fda compounding semaglutide crackdown november 2025 The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the November 2025 Drug Safety: Recalls

Several, independent meta-analyses have reported that the majority of patients with bipolar disorder experience problems with memory loss and cognition across all phases of the disorder, even during periods of remission in a manner that increases with recurrence [101,102,103]

In particular, researchers are focused on whether medications that influence appetite and metabolic signaling may also affect pathways involved in craving, motivation, and reinforcement

On medication, Found offers more options than any other program: compounded GLP-1s starting at $99/month (with flat pricing as your dose increases), branded GLP-1s like Wegovy and Zepbound with insurance navigation support or direct-pay options, and non-GLP-1 plan options starting at $49/month

Regular glucose monitoring remains advisable regardless

Cost trajectory over treatment: Months 1-3 (0.05-0.125 mg): $150-$200/month Months 4-6 (0.25-0.5 mg): $200-$250/month Months 7+ (1-2 mg maintenance): $250-$300/month Best for budget-conscious patients and first-time GLP-1 users seeking an affordable entry